Shopping Cart
- Remove All
Your shopping cart is currently empty
Tyrphostin 8
Tyrphostin 8(4-Hydroxybenzylidenemalononitrile) is a potent GTPase inhibitor that inhibits EGFR kinase with an IC50 of 560 μM.Tyrphostin 8 inhibits protein serine/threonine calmodulin phosphatases (IC50=21 μM), enhances transferrin receptor-mediated transcytosis in Caco-2 cells, and increases the hypoglycemic effect of oral insulin-transferrin. hypoglycemic effect.
Catalog No. T34973Cas No. 3785-90-8
Select Batch
Purity:99.86%
Contact us for more batch information
Tyrphostin 8
Catalog No. T34973Alias 4-HydroxybenzylidenemalononitrileCas No. 3785-90-8
Tyrphostin 8(4-Hydroxybenzylidenemalononitrile) is a potent GTPase inhibitor that inhibits EGFR kinase with an IC50 of 560 μM.Tyrphostin 8 inhibits protein serine/threonine calmodulin phosphatases (IC50=21 μM), enhances transferrin receptor-mediated transcytosis in Caco-2 cells, and increases the hypoglycemic effect of oral insulin-transferrin. hypoglycemic effect.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $31 | In Stock | |
| 10 mg | $45 | In Stock | |
| 25 mg | $73 | In Stock | |
| 50 mg | $106 | In Stock | |
| 100 mg | $157 | In Stock | |
| 500 mg | $389 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Tyrphostin 8"
Stearic acid
Octadecanoic acid, Isostearic acid, Cetylacetic acid
T2P292357-11-4
1. Stearic acid (Cetylacetic acid) can reduce metastatic tumor burden. 2. Stearic acid leads to dramatically reduced visceral fat likely by causing the apoptosis of preadipocytes. 3. Stearic acid and its derivatives have been used as gelators in food and pharmaceutical gel formulations. 4. Stearic acid is a potent phosphatase 1B inhibitor, possibly causing an enhancement in the insulin receptor signaling to stimulate glucose uptake into adipocytes. 5. Stearic acid has the potential to increase dry matter intake and yields of milk and milk components, without affecting conversion of feed to milk, body condition score, or body weight.
- $33
Size
QTY
Gefitinib
Cited
ZD1839
T1181184475-35-2
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
- $50
Size
QTY
CitedTartaric acid disodium dihydrate
Disodium L-(＋)-Tartrate Dihydrate
T651286106-24-7
Tartaric acid disodium dihydrate (Disodium L-(＋)-Tartrate Dihydrate) is commonly used as a buffer in molecular biology and cell culture.Tartaric acid disodium dihydrate is an acid phosphatase inhibitor that increases the probability of colchicine binding to tubulin1.
- $32
Size
QTY
Cyclosporine
T645979217-60-0
Cyclosporine is a calcineurin phosphatase pathway inhibitor, used as an immunosuppressant drug to prevent rejection in organ transplantation.
- $30
Size
QTY
β-Glycerophosphate disodium salt pentahydrate
β-Glycerol phosphate disodium salt pentahydrate, BETA-GLYCEROL PHOSPHATE DISODIUM SALT
T587813408-09-8
β-Glycerophosphate disodium salt pentahydrate is a protein phosphatase inhibitor.
- $58
Size
QTY
Erlotinib Cited
R1415, OSI-744, NSC 718781, CP358774
T0373183321-74-6
Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
- $40
Size
QTY
CitedOsimertinib Cited
Mereletinib, AZD-9291
T24901421373-65-0
Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.
- $32
Size
QTY
CitedLapatinib Cited
GW572016, GSK572016
T0078231277-92-2
Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.
- $29
Size
QTY
CitedNeratinib Cited
HKI-272
T2325698387-09-6
Neratinib (HKI-272) (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor for HER2 and EGFR (IC50: 59/92 nM), respectively.
- $30
Size
QTY
CitedGenistein Cited
NPI 031L
T1737446-72-0
Genistein (NPI 031L) is a naturally occurring soy isoflavone, a multi-targeted tyrosine kinase inhibitor. Genistein has antitumor, antioxidant, and anthelmintic properties, and also produces estrogen-like effects in the body.
- $38
Size
QTY
CitedIdoxuridine
SKF 14287, NSC 39661, IDU, Dendrid, 5-IUdR, 5-Iodo-2′-deoxyuridine
T086354-42-2
Idoxuridine (Dendrid) is an analog of DEOXYURIDINE that inhibits viral DNA synthesis. The drug is used as an antiviral agent.
- $30
Size
QTY
Erlotinib hydrochloride
OSI-744, NSC 718781, Erlotinib HCl, CP-358774
T0373L183319-69-9
Erlotinib hydrochloride (NSC 718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
- $35
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
| Description | Tyrphostin 8(4-Hydroxybenzylidenemalononitrile) is a potent GTPase inhibitor that inhibits EGFR kinase with an IC50 of 560 μM.Tyrphostin 8 inhibits protein serine/threonine calmodulin phosphatases (IC50=21 μM), enhances transferrin receptor-mediated transcytosis in Caco-2 cells, and increases the hypoglycemic effect of oral insulin-transferrin. hypoglycemic effect. |
| Targets&IC50 | EGFR:560 μM (IC50), Calcineurin phosphatase:21 μM (IC50) |
| In vitro | Pretreated for 20 minutes at concentrations ranging from 10 to 100 μM, Tyrphostin 8 blocks Carbachol-initiated PKCδ tyrosine phosphorylation and ERK1/2 activation in parotid acinar cells[1]. Additionally, at concentrations of 10-100 μM, Tyrphostin 8 induces a rapid and substantial increase in the basal O2 consumption of parotid acinar cells[1]. Furthermore, at a concentration of 100 μM, Tyrphostin 8 reduces parotid ATP content by approximately 90%[1]. In another context, Tyrphostin 8 enhances the apical-to-basolateral transport of insulin-transferrin conjugate by promoting transferrin receptor-mediated transcytosis in filter-grown Caco-2 cell monolayers[2]. |
| In vivo | In Streptozotocin-induced diabetic rats, Tyrphostin 8 enhances the glucose-lowering effect of insulin-transferrin[2]. |
| Alias | 4-Hydroxybenzylidenemalononitrile |
| Molecular Weight | 170.17 |
| Formula | C10H6N2O |
| Cas No. | 3785-90-8 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (293.82 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Tyrphostin 8 | purchase Tyrphostin 8 | Tyrphostin 8 cost | order Tyrphostin 8 | Tyrphostin 8 chemical structure | Tyrphostin 8 in vivo | Tyrphostin 8 in vitro | Tyrphostin 8 formula | Tyrphostin 8 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.